Heart rate as a predictor of stroke in high-risk, hypertensive patients with previous stroke or transient ischemic attack

Journal of Stroke and Cerebrovascular Diseases

Volumn 23, Issue 10, 2014, Pages 2814-2818

  Sandset, Else Charlotte ^a   Berge, Eivind ^a   Kjeldsen, Sverre E ^a,b,c   Julius, Stevo ^c   Holzhauer, Björn ^d   Krarup, Lars Henrik ^e   Hua, Tsushung A ^d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Heart rate; Hypertension; Predictors; Recurrence; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; TETRAZOLE DERIVATIVE; VALINE;

AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART RATE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESTING HEART RATE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DOUBLE BLIND PROCEDURE; ISCHEMIC ATTACK, TRANSIENT; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; STROKE; TIME; TREATMENT OUTCOME;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; HYPERTENSION; ISCHEMIC ATTACK, TRANSIENT; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; STROKE; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE;

EID: 84923264391     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2014.07.009     Document Type: Article

References (36)

1. Hillen T, Coshall C, Tilling K, et al. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke 2003;34:1457-1463.
2. Sacco RL, Wolf PA, Kannel WB, et al. Survival and recurrence following stroke. The Framingham study. Stroke 1982;13:290-295.
3. Mohan KM, Crichton SL, Grieve AP, et al. Frequency and predictors for the risk of stroke recurrence up to 10 years after stroke: the South London Stroke Register. J Neurol Neurosurg Psychiatry 2009;80:1012-1018.
4. van Wijk I, Kappelle LJ, van Gijn J, et al. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 2005;365:2098-2104.
5. Hankey GJ. Long-term outcome after ischaemic stroke/ transient ischaemic attack. Cerebrovasc Dis 2003; 16(Suppl 1):14-19.
6. Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998;29:2491-2500.
7. Dhamoon MS, Tai W, Boden-Albala B, et al. Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study. Stroke 2007;38:1752-1758.
8. Dhamoon MS, Moon YP, Paik MC, et al. Long-term functional recovery after first ischemic stroke: the Northern Manhattan Study. Stroke 2009;40:2805-2811.
9. Petty GW, Brown RD Jr, Whisnant JP, et al. Survival and recurrence after first cerebral infarction: a populationbased study in Rochester, Minnesota, 1975 through 1989. Neurology 1998;50:208-216.
10. Hart RG, Pearce LA, Bakheet MF, et al. Predictors of stroke recurrence in patients with recent lacunar stroke and response to interventions according to risk status: secondary prevention of small subcortical strokes trial. J Stroke Cerebrovasc Dis 2014;23:618-624.
11. Elkind MS. Outcomes after stroke: risk of recurrent ischemic stroke and other events. Am J Med 2009; 122:S7-13.
12. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012; 109:685-692.
13. Paul L, Hastie CE, Li WS, et al. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension 2010;55:567-574.
14. Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008;29:1327-1334.
15. Okin PM, Kjeldsen SE, Julius S, et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 2010;31:2271-2279.
16. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885.
17. Bohm M, Cotton D, Foster L, et al. Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. Eur Heart J 2012; 33:2804-2812.
18. Custodis F, Gertz K, Balkaya M, et al. Heart rate contributes to the vascular effects of chronic mental stress: effects on endothelial function and ischemic brain injury in mice. Stroke 2011;42:1742-1749.
19. Julius S, Kjeldsen SE, Brunner H, et al. VALUE trial: longterm blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003;16:544-548.
20. Julius S, Kjeldsen SE,Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031.
21. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-2051.
22. Mann J, Julius S. The Valsartan Antihypertensive Longterm Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998;7:176-183.
23. Kjeldsen SE, Julius S, Brunner H, et al. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Longterm Use Evaluation. Blood Press 2001;10:83-91.
24. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006; 24:2163-2168.
25. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976; 54:541-553.
26. Molloy TJ, Okin PM, Devereux RB, et al. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol 1992;20:1180-1186.
27. Okin PM, Roman MJ, Devereux RB, et al. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995;25:417-423.
28. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949;37:161-186.
29. Poulter NR, Dobson JE, Sever PS, et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 2009;54:1154-1161.
30. Williams B, Lacy PS. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFEHeart Rate. J Am Coll Cardiol 2009;54:705-713.
31. Callahan A,Amarenco P, Goldstein LB, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol 2011;68:1245-1251.
32. Alter M, Lai SM, Friday G, et al. Stroke recurrence in diabetics. Does control of blood glucose reduce risk? Stroke 1997;28:1153-1157.
33. Kjeldsen SE, Okin PM. High resting heart rate predicts mortality, disability, and cognitive decline in patients after ischaemic stroke: time for additional selective I(f) channel inhibitor trials? Eur Heart J 2012;33:2761-2763.
34. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001;12:218-225.
35. de Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004;164:2459-2464.
36. Ruilope LM, Zanchetti A, Julius S, et al. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens 2007;25:1473-1479.